<DOC>
	<DOCNO>NCT00134563</DOCNO>
	<brief_summary>The primary objective determine effect teriflunomide frequency relapse patient relapse multiple sclerosis ( MS ) . Secondary objective : - evaluate effect teriflunomide accumulation disability measure Expanded Disability Status Scale [ EDSS ] , burden disease measure Magnetic Resonance Imaging [ MRI ] patient-reported fatigue ; - evaluate safety tolerability teriflunomide .</brief_summary>
	<brief_title>Study Teriflunomide Reducing Frequency Relapses Accumulation Disability Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The study period per participant approximatively 128 week broken follow : - Screening period 4 week , - 108-week double-blind treatment period ( approximatively 2 year ) * , - 16-week post-treatment elimination follow-up period . '* ' Participants successfully complete week 108 visit offer opportunity enter optional long-term extension study LTS6050 - NCT00803049 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Multiple sclerosis [ MS ] subject ambulatory ( EDSS â‰¤ 5.5 ) Exhibiting relapse clinical course , without progression ( relapse remitting , secondary progressive progressive relapsing ) ; Meeting McDonald 's criterion MS diagnosis ; Experienced least 1 relapse 1 year precede trial least 2 relapse 2 year precede trial ; No relapse onset precede 60 day prior randomization ; Clinically stable 30 day prior randomization , without adrenocorticotrophic hormone [ ACTH ] systemic steroid treatment . Clinically relevant cardiovascular , hepatic , neurological , endocrine major systemic disease ; Significantly impair bone marrow function ; Pregnant nursing woman ; Alcohol drug abuse ; Use cladribine , mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporin , methotrexate mycophenolate enrollment ; Any known condition circumstance would prevent investigator 's opinion compliance completion study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Remitting</keyword>
	<keyword>Secondary Progressive</keyword>
	<keyword>Progressive Relapsing</keyword>
</DOC>